Apr 20, 2009 0
Stocks to watch – Dendreon (DNDN)
Shares of Dendreon (DNDN) skyrocketed Tuesday after the Seattle biotech company announced positive results in a clinical trial for its prostate cancer drug Provenge.
The stock nearly tripled in early trading before pulling back slightly, indicating that a potent mix of a short squeeze and increased hopes that the Food and Drug Administration will approve the drug were at work on the volatile stock.
Continue reading Stocks to watch – Dendreon (DNDN)

Recent Comments